You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 164 No. 5, March 8, 2004 TABLE OF CONTENTS
  Archives
  •  Online Features
  Special Article
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on ISI (13)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Topic Collections
 •Diabetes Mellitus
 •Alert me on articles by topic

Optimal Glycemic Control in Type 2 Diabetes Mellitus

Fasting and Postprandial Glucose in Context

Martin J. Abrahamson, MD

Arch Intern Med. 2004;164:486-491.

Type 2 diabetes mellitus is the consequence of both insulin resistance and impaired insulin secretion. In the progression from normal glucose tolerance to diabetes, postprandial glucose (PPG) levels often rise before fasting plasma glucose (FPG) levels increase above 126 mg/dL (7.0 mmol/L). Numerous epidemiologic studies have shown that impaired glucose tolerance is associated with increased risk for macrovascular disease and that isolated postchallenge hyperglycemia is an independent factor for increased mortality. Reducing the risk for microvascular complications by improving glycosylated hemoglobin (HbA1c) levels is well documented. Emerging data now support the relationship between glycemic control and macrovascular disease. Epidemiologic studies documenting postprandial hyperglycemia and the risk for increased mortality suggest that lowering PPG levels might be beneficial. Optimizing both FPG and PPG is important in achieving normal/near-normal glucose levels. Many patients with type 2 diabetes have difficulty attaining the recommended HbA1c goal despite normal/near-normal FPG levels; thus, pharmacologic treatment targeting PPG levels may prove beneficial.


From the Joslin Diabetes Center and Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Mass. Dr Abrahamson has been on the speakers' bureau for the following companies: Aventis, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Novo Nordisk, Novartis, and Pfizer.



THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Changes in Depressive Symptoms and Glycemic Control in Diabetes Mellitus
Georgiades et al.
Psychosom. Med. 2007;69:235-241.
ABSTRACT | FULL TEXT  

Treatment of Type 2 Diabetes Mellitus: A Weighty Enigma
Comi
ANN INTERN MED 2005;143:609-610.
FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2004 American Medical Association. All Rights Reserved.